Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas

(2013) K. Walsh et al.   CLINICAL CANCER RESEARCH

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

(2012) Annett Mueller et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo

(2012) Hui Ren et al.   CANCER LETTERS

Molecules and their functions in autophagy

(2012) Jong-Ok Pyo et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

(2012) S. M. Brachmann et al.   MOLECULAR CANCER THERAPEUTICS

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

(2012) Roland Schmitz et al.   NATURE

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs

(2012) Bryan A. Gibson et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells

(2012) Christopher R. Zito et al.   PLoS One

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

(2011) M. Gupta et al.   BLOOD

Autophagy as a therapeutic target in cancer

(2011) Ning Chen et al.   CANCER BIOLOGY & THERAPY

Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

(2011) D. Koul et al.   CLINICAL CANCER RESEARCH

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone

(2011) Yuhuan Zheng et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Role of Bcl-2 family proteins and caspases in the regulation of apoptosis

(2011) Mohammad Shamsul Ola et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Germinal center B-cell-like diffuse large B-cell lymphoma of the duodenum is associated with t(14;18) translocation

(2011) Maiko Tamura et al.   PATHOLOGY INTERNATIONAL

A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors

(2011) Shujie Yang et al.   PLoS One

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling

(2010) Xin He et al.   CANCER LETTERS

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

PTENtumor suppressor plays less prognostic role thanP53tumor suppressor in diffuse large B-cell lymphoma

(2010) Yan-Yan Liu et al.   LEUKEMIA & LYMPHOMA

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells

(2010) B. Kloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autophagosome formation in mammalian cells

(2010) Chloe Burman et al.   Seminars in Immunopathology

Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy

(2009) M. Y. Zhao et al.   CLINICAL CANCER RESEARCH

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002

(2008) J. Werzowa et al.   BRITISH JOURNAL OF DERMATOLOGY

Mcl-1 is a potential therapeutic target in multiple types of cancer

(2008) C. Akgul   CELLULAR AND MOLECULAR LIFE SCIENCES

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

(2008) Dana M. Gwinn et al.   MOLECULAR CELL

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE